米诺卡生物标志物:非动脉样硬化方面
Xiaojian Xu1, Guoliang Zhang1, Zhaoqing Li1
1Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao 266100, China.
Clinica chimica acta; international journal of clinical chemistry
|October 23, 2023
概括
没有阻塞性冠状动脉疾病 (MINOCA) 的心肌梗塞,尽管原因不明,但存在重大风险. 识别生物标志物对于更好的诊断,个性化治疗和预测MINOCA患者的结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 生物标志物发现发现
- 病理生理学 病理生理学
背景情况:
- 在没有阻塞性冠状动脉疾病 (MINOCA) 的情况下的心肌梗塞是一个重要的临床挑战.
- 尽管MINOCA占心肌梗塞病例的很大一部分,但其诊断和管理仍然很困难.
- 目前尚不完全了解MINOCA的潜在病理生理学,导致诊断和治疗不确定性.
研究的目的:
- 审查目前MINOCA的诊断和治疗方法.
- 强调识别MINOCA新生物标志物的重要性.
- 讨论生物标志物在改善MINOCA的诊断,治疗个性化和结果预测方面的潜力.
主要方法:
- 关于MINOCA诊断和生物标志物研究的文献综述.
- 分析目前对MINOCA病理生理学的理解.
- 在MINOCA的背景下讨论新兴生物标志物研究.
主要成果:
- 尽管有各种推的方法,最终诊断MINOCA仍然具有挑战性.
- 缺乏对MINOCA病理生理学的全面了解,使临床管理复杂化.
- 生物标志物识别是改善MINOCA护理的活跃研究领域.
结论:
- 需要改善MINOCA的诊断策略.
- 对MINOCA病理生理学和生物标志物发现的进一步研究是必不可少的.
- 生物标志物有望提高MINOCA的临床管理和预后.
相关概念视频
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
19
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
19
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
11
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
11
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
99
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
99
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
174
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
174
Coronary Artery Disease I: Introduction
17
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
17
Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11


